Journal article
Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma
Abstract
Aim: To evaluate optimal systemic therapy sequencing (first-line targeted therapy (1L-TT) vs. first-line immunotherapy (1L-IO)) in patients with BRAF-mutated metastatic melanoma. Methods: Nation-wide prospective data of patients with newly diagnosed BRAF-mutated metastatic melanoma were retrieved from the Canadian Melanoma Research Network. Results: Our study included 79 and 107 patients in the 1L-IO and 1L-TT groups, respectively. There were …
Authors
Kartolo A; Deluce J; Hopman WM; Liu L; Baetz T; Ernst S; Lenehan JG
Journal
Current Oncology, Vol. 29, No. 3, pp. 1501–1513
Publisher
MDPI
DOI
10.3390/curroncol29030126
ISSN
1198-0052